Do analysts recommend CNSP or PTPI?

CNS Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 281.39%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CNSP or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Petros Pharmaceuticals N/A -78.22% -23.50%

Do analysts rate CNSP or APLM?

CNS Pharmaceuticals presently has a consensus price target of $20.00, suggesting a potential upside of 281.39%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CNSP or APLM?

Apollomics has higher revenue and earnings than CNS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A Apollomics $8.50M 3.61 -$10.94M N/A N/A

Is CNSP or APLM more profitable?

Apollomics' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Apollomics N/A N/A N/A

Do analysts rate CPHI or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 281.39%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CNSP or SNTI more profitable?

CNS Pharmaceuticals' return on equity of -238.68% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Senti Biosciences N/A -532.05% -103.35%

Does the media favor CNSP or SNTI?

In the previous week, CNS Pharmaceuticals' average media sentiment score of 1.89 equaled Senti Biosciences'average media sentiment score. Company Overall Sentiment CNS Pharmaceuticals Very Positive Senti Biosciences Very Positive

Do analysts prefer MYNZ or CNSP?

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 281.39%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MYNZ or CNSP more profitable?

Mainz Biomed's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A CNS Pharmaceuticals N/A -238.68% -166.30%

CNS Pharmaceuticals (CNSP) Competitors

$5.24 +0.00 (+0.08%)

As of 03:36 PM Eastern

Compare

CNSP vs. PTPI, APLM, CPHI, SNTI, and MYNZ

Should you buy CNS Pharmaceuticals stock or one of its competitors? MarketBeat compares CNS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CNS Pharmaceuticals include Petros Pharmaceuticals (PTPI), Apollomics (APLM), China Pharma (CPHI), Senti Biosciences (SNTI), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry.

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

CNS Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 281.39%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Petros Pharmaceuticals had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for Petros Pharmaceuticals and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.89 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Very Positive
Petros Pharmaceuticals	Neutral

CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Apollomics?

CNS Pharmaceuticals (NASDAQ:CNSP) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Apollomics' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Apollomics	N/A	N/A	N/A

CNS Pharmaceuticals has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Apollomics has higher revenue and earnings than CNS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Apollomics	$8.50M	3.61	-$10.94M	N/A	N/A

In the previous week, CNS Pharmaceuticals' average media sentiment score of 1.89 beat Apollomics' score of 1.87 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Very Positive
Apollomics	Very Positive

CNS Pharmaceuticals presently has a consensus price target of $20.00, suggesting a potential upside of 281.39%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CNS Pharmaceuticals beats Apollomics on 6 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to China Pharma?

China Pharma (NYSE:CPHI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

China Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, suggesting that its stock price is 206% more volatile than the broader market.

CNS Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

14.0% of CNS Pharmaceuticals shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, China Pharma had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for China Pharma and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.89 beat China Pharma's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
CNS Pharmaceuticals	Very Positive

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 281.39%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

China Pharma has higher revenue and earnings than CNS Pharmaceuticals. China Pharma is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	8.57	-$3.08M	-$0.55	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

Summary

CNS Pharmaceuticals beats China Pharma on 8 of the 15 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Senti Biosciences?

CNS Pharmaceuticals (NASDAQ:CNSP) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

CNS Pharmaceuticals has higher earnings, but lower revenue than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Senti Biosciences	$20K	1,565.29	-$61.44M	-$1.92	N/A

CNS Pharmaceuticals currently has a consensus price target of $20.00, indicating a potential upside of 281.39%. Senti Biosciences has a consensus price target of $8.75, indicating a potential upside of 770.65%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

CNS Pharmaceuticals' return on equity of -238.68% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Senti Biosciences	N/A	-532.05%	-103.35%

In the previous week, CNS Pharmaceuticals' average media sentiment score of 1.89 equaled Senti Biosciences'average media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Very Positive
Senti Biosciences	Very Positive

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

Summary

Senti Biosciences beats CNS Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mainz Biomed's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 281.39%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CNS Pharmaceuticals' average media sentiment score of 1.89 beat Mainz Biomed's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
CNS Pharmaceuticals	Very Positive

CNS Pharmaceuticals has lower revenue, but higher earnings than Mainz Biomed. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	33.77	-$21.65M	-$65.60	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

Summary

CNS Pharmaceuticals beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNSP vs. The Competition

Export

Metric	CNS Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.66M	$3.34B	$6.43B	$12.49B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.18	18.86	23.86	24.42
Price / Sales	N/A	320.30	521.12	117.04
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.72	6.81	10.04	6.74
Net Income	-$15.85M	$24.09M	$3.56B	$337.03M
7 Day Performance	7.24%	-2.39%	-0.81%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-58.77%	48.97%	28.80%	34.36%

CNS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNSP CNS Pharmaceuticals	3.8935 of 5 stars	$5.24 +0.1%	$20.00 +281.4%	-56.8%	$7.66M	N/A	N/A	5	Gap Down
PTPI Petros Pharmaceuticals	N/A	$0.01 flat	N/A	-81.6%	$190K	$5.11M	N/A	20	Gap Up
APLM Apollomics	1.1933 of 5 stars	$14.09 -1.5%	N/A	+115.7%	$30.93M	$8.50M	N/A	45	Positive News
CPHI China Pharma	N/A	$0.76 +0.0%	N/A	-46.0%	$30.80M	$3.99M	N/A	250
SNTI Senti Biosciences	3.2555 of 5 stars	$0.99 +0.5%	$8.75 +781.9%	-69.0%	$30.74M	$20K	N/A	4	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNSP) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, APLM, CPHI, SNTI, and MYNZ

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to Apollomics?

Summary

How does CNS Pharmaceuticals compare to China Pharma?

Summary

How does CNS Pharmaceuticals compare to Senti Biosciences?

Summary

How does CNS Pharmaceuticals compare to Mainz Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, APLM, CPHI, SNTI, and MYNZ

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Do analysts recommend CNSP or PTPI?

Is CNSP or PTPI more profitable?

Which has preferable valuation & earnings, CNSP or PTPI?

Do institutionals & insiders believe in CNSP or PTPI?

Does the media refer more to CNSP or PTPI?

Which has more volatility & risk, CNSP or PTPI?

Summary

How does CNS Pharmaceuticals compare to Apollomics?

Is CNSP or APLM more profitable?

Which has more volatility & risk, CNSP or APLM?

Do institutionals and insiders have more ownership in CNSP or APLM?

Which has stronger valuation and earnings, CNSP or APLM?

Does the media refer more to CNSP or APLM?

Do analysts rate CNSP or APLM?

Summary

How does CNS Pharmaceuticals compare to China Pharma?

Which has more volatility and risk, CPHI or CNSP?

Is CPHI or CNSP more profitable?

Do insiders & institutionals have more ownership in CPHI or CNSP?

Does the media refer more to CPHI or CNSP?

Do analysts rate CPHI or CNSP?

Which has higher valuation & earnings, CPHI or CNSP?

Summary

How does CNS Pharmaceuticals compare to Senti Biosciences?

Which has better valuation & earnings, CNSP or SNTI?

Do analysts recommend CNSP or SNTI?

Is CNSP or SNTI more profitable?

Does the media favor CNSP or SNTI?

Do institutionals & insiders have more ownership in CNSP or SNTI?

Which has more volatility & risk, CNSP or SNTI?

Summary

How does CNS Pharmaceuticals compare to Mainz Biomed?

Which has more volatility and risk, MYNZ or CNSP?

Do institutionals and insiders have more ownership in MYNZ or CNSP?

Is MYNZ or CNSP more profitable?

Do analysts prefer MYNZ or CNSP?

Does the media refer more to MYNZ or CNSP?

Which has better earnings and valuation, MYNZ or CNSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools